Clinical study on peripheral regional therapy for central neuropathic pain

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061679

Enrollment

Unknown

Registered

2022-06-30

Start date

2022-06-30

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central neuropathic pain

Interventions

Test group:Peripheral nerve block

Control group:Saline injection

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Central neuropathic pain affecting the upper and/or lower extremities; 3. Meet the NeuPSIG (International Association for the Study of Pain Neuropathic Pain Special Interest Group) diagnostic criteria for central neuropathic pain: (1) Meets all mandatory criteria: 1) The site of pain corresponds to a central nervous system lesion; 2) A clear history of neurological disease; 3) History of spinal cord injury, stroke, multiple sclerosis, or other CNS pathology confirmed by imaging (e.g., CT, MRI, neurophysiological or biochemical examinations); 4) Exclusion of other causes of pain (e.g., musculoskeletal pain due to spasticity, myofascial shoulder pain, heterotopic ossification, overuse syndrome, other musculoskeletal pain, visceral pain, and peripheral neuropathic pain); (2) At least 1 supporting criterion exists: 1) No primary relationship to exercise, inflammation, or other local tissue injury; 2) Presence of descriptors such as burning pain, cold tingling, electric shock, pain, pressure, numbness, and pins and needles. 3) The presence of abnormal pain or dullness of sensation to touch or cold; 4. Spontaneous pain of intensity =4 on the 0-10 Numerical Rating Scale (NRS).

Exclusion criteria

Exclusion criteria: 1. Inability or unwillingness to provide informed consent; 2. Severe mental or cognitive impairment; 3. Moderate to severe renal or hepatic failure; 4. The presence of other diagnoses that could explain neuropathic pain; 5. Contraindication to treatment with warfarin or other anticoagulants as regional anesthesia; 6. Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Reduction in Numeric Rating Scales score for spontaneous pain;	—

Secondary

Measure	Time frame
Neuropathic pain symptom scale score;Activities of daily living ability (modified Barthel index);Sensory test score;Intent to reinject;Willingness to recommend the program to others;	—

Countries

China

Contacts

Public ContactZhenyu Wang

Yongchuan Hospital of Chongqing Medical University

wangzhenyudr@163.com+86 17783866168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026